{
    "clinical_study": {
        "@rank": "97274", 
        "acronym": "DES", 
        "arm_group": [
            {
                "arm_group_label": "DA-6034 Low dose", 
                "arm_group_type": "Experimental", 
                "description": "DA-6034 3%"
            }, 
            {
                "arm_group_label": "DA-6034 High dose", 
                "arm_group_type": "Experimental", 
                "description": "DA-6034 5%"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "DA-6034 Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is to determine the efficacy and safety of 3% or 5% DA-6034 eye drops compared\n      with placebo in dry eye syndrome."
        }, 
        "brief_title": "Phase II Study of DA-6034 Eye Drops in Dry Eye Syndrome", 
        "completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "condition": "Dry Eye Syndrome", 
        "condition_browse": {
            "mesh_term": [
                "Dry Eye Syndromes", 
                "Keratoconjunctivitis Sicca"
            ]
        }, 
        "detailed_description": {
            "textblock": "Eligible subjects are randomly assigned to receive 3% DA-6034, 5% DA-6034 or Placebo. This\n      study is conducted for 6 weeks(Run-in Period 2 weeks + Treatment Period 4 weeks)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Age\u226520\n\n          2. Dry eye symptoms(irritation, foreign body sensation, burning, mucus discharge,\n             blurring, itching, photophobia, tird or heavy feeling, pain) for more than 6 months\n\n          3. Fluorescein corneal staining score \u2265 4 and Schirmer test I \u2264 7mm in same eye\n\n          4. Corrected vision \u2265 0.2 in both eye\n\n          5. Have given a written, informed consent\n\n        Exclusion Criteria:\n\n          1. Ocular disorder that may confound interpretation of study results\n\n          2. Current treatment for glaucoma or IOP over 25mmHg\n\n          3. Ocular surgery history within 1 year\n\n          4. Other malignancy history or uncontrolled severe disease within 5 years\n\n          5. Use of systemic immunosuppressive therapies within 3 months\n\n          6. Use of opthalmic cyclosporin, opthalmic steroid within 4 weeks\n\n          7. Received any other investigational drugs within 4 weeks\n\n          8. Subjects who are willing to wear contact lenses during study participation\n\n          9. Pregnant or lactating women"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 19, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01670357", 
            "org_study_id": "DA6034_DES_II"
        }, 
        "intervention": [
            {
                "arm_group_label": "DA-6034 Low dose", 
                "description": "Eye drop, 1 drop/each eye, 4 times/day, for 4 weeks", 
                "intervention_name": "DA-6034 3%", 
                "intervention_type": "Drug", 
                "other_name": "DA-6034 Low dose"
            }, 
            {
                "arm_group_label": "DA-6034 High dose", 
                "description": "Eye drop, 1 drop/each eye, 4 times/day, for 4 weeks", 
                "intervention_name": "DA-6034 5%", 
                "intervention_type": "Drug", 
                "other_name": "DA-6034 High dose"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Eye drop, 1 drop/each eye, 4 times/day, for 4 weeks", 
                "intervention_name": "DA-6034 Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Placebo"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Tetrahydrozoline"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Dry Eye Syndrome", 
        "lastchanged_date": "August 13, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "137-701"
                }, 
                "name": "Seoul St.Mary's hospital"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "3", 
        "official_title": "Placebo Controlled, Dose-Response, Randomized, Double Blind, Phase II Study to Evaluate the Efficacy and Safety of DA-6034 Eye Drops in Patients With Dry Eye Syndrome", 
        "overall_official": {
            "affiliation": "Seoul St. Mary's Hospital", 
            "last_name": "ManSoo Kim, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "South Korea: Korea Food and Drug Administration (KFDA)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Change from baseline means the change between 0 weeks and 4 weeks.", 
            "measure": "Change from baseline of Fluorescein Corneal Staining(FCS) score", 
            "safety_issue": "No", 
            "time_frame": "4 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01670357"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Change from baseline means the change between 0 weeks and 4 weeks.", 
                "measure": "Change from baseline of Tear Break-Up Time(TBUT)", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }, 
            {
                "description": "Change from baseline means the change between 0 weeks and 4 weeks.", 
                "measure": "Change from baseline of Lissamine Green Conjunctival Staining(LGCS) score", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }, 
            {
                "description": "Change from baseline means the change between 0 weeks and 4 weeks.", 
                "measure": "Change from baseline of Schirmer Test I score", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }, 
            {
                "description": "Change from baseline means the change between 0 weeks and 4 weeks.", 
                "measure": "Change from baseline of Ocular Surface Disease Index(OSDI) score", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }
        ], 
        "source": "Dong-A Pharmaceutical Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Dong-A Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}